Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' EQUITY

v3.19.1
STOCKHOLDERS' EQUITY
3 Months Ended
Mar. 31, 2019
Equity [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
3. STOCKHOLDERS’ EQUITY
 
July 2018 Public Offering
 
On July 31, 2018, the Company sold 1,355,000 shares of common stock, 1,114 shares of Series C Convertible Preferred Stock (the “Series C Preferred Stock”) convertible into 2,785,000 shares of common stock and Series E warrants to purchase 4,140,000 shares of common stock. The public offering price of a share of common stock together with a Series E warrant to purchase one share of common stock was $4.00. The public offering price of a share of
Series C Preferred Stock, each of which is convertible into 2,500 shares of Common Stock, together with a Series E warrant to purchase 2,500 shares of common stock
was $10,000. The Series E warrants have an exercise price of $4.00 per share and are exercisable until July 31, 2023. Gross offering proceeds to the Company were $16.56 million, with net proceeds to the Company of approximately $15.0 million after deducting underwriting discounts and commissions and related offering expenses.
 
In order to account for the July 2018 public offering, the Company allocated the proceeds to the common stock, the Series C Preferred Stock and the Series E warrants on a relative fair value basis. Then using the effective conversion price of the Series C Preferred Stock, the Company determined that there was a beneficial conversion feature (“BCF”) of $2,241,795. The BCF did not impact total Stockholders’ Equity but was reflected as a deemed dividend in arriving at net loss attributable to common stockholders in July 2018
.
 
The Series C Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock), liquidation preference or other preferences over common stock, and subject to limited exceptions, has no voting rights.
For the three and twelve months ended
 
March 31, 2019 and December 31, 2018, 138 and 641 shares of Series C Preferred Stock were converted into 345,000 and 1,602,500 shares of common stock, respectively.
 
Reverse Stock Split
 
At a special meeting held on July 12, 2018, our stockholders approved an amendment to our certificate of incorporation to affect a reverse split of our common stock at a ratio between 1:5 to 1:10 and authorized the Board to determine the ratio at which the reverse split would be. The Board authorized the ratio of the reverse split, and effective at the close of business on July 16, 2018, the Company implemented a 1-for-10 reverse stock split of its outstanding common stock. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock that the Company is authorized to issue remains unchanged at
80,000,000
and the par value remains at $
0.00001
per share. Accordingly, stockholders’ equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.
 
Common Stock Warrants
 
The following table summarizes information with regard to outstanding warrants to purchase common stock as of March 31, 2019.
 
Offering
 
Number of Shares

Issuable Upon

Exercise of

Outstanding

Warrants
 
 
Exercise

Price
 
 
Expiration Date
 
July 2018 Series E Warrants
 
 
4,140,000
 
 
$
4.00
 
 
 
July 31, 2023
 
October 2017 Series D Warrants
 
 
310,856
 
 
$
17.80
 
 
 
October 14, 2024
 
November 2016 Public Offering Series C
 
 
415,785
 
 
$
15.00
 
 
 
November 29, 2021
 
April 2016 Underwritten Registered Series A
 
 
362,694
 
 
$
30.40
 
 
 
April 20,2021
 
October 2015 Incremental Series A
 
 
30,006
 
 
$
21.30
 
 
 
October 20,202
1
 
October 2015 Private Placement Series A
 
 
8,636
 
 
$
21.30
 
 
 
April 1, 2021
 
October 2015 Offering – Placement Agent
 
 
375
 
 
$
283.00
 
 
 
October 1, 2020
 
August 2014 Public Offering
(1)
 
 
50,395
 
 
$
468.00
 
 
 
August 20, 2019
 
Total
 
 
5,318,747
 
 
 
 
 
 
 
 
 
 
 
(1)
These warrants have a certain type of cash settlement feature and they have been accounted for as derivative instruments as described in Note 1, with the exception of
970
warrants issued in August 2014.